Retatrutide 20mg

Description

A potent triple-hormone agonist (GLP-1/GIP/GCG) provided in a 20mg vial for advanced metabolic and biochemical research.

Retatrutide 20mg is a triple agonist peptide currently at the forefront of metabolic research. As a multi-receptor agonist, it targets the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors. This unique mechanism of action allows researchers to investigate the synergistic effects of triple-hormone activation on metabolic pathways, energy expenditure, and glucose homeostasis in laboratory models. Derived from the original GIP sequence, Retatrutide is engineered for enhanced stability and receptor affinity across all three targets. Its development represents a significant evolution from mono and dual-agonist compounds, providing a complex tool for studying the physiological implications of integrated hormonal signaling. This 20mg presentation is provided as a highly purified lyophilised powder, ensuring structural integrity for precise laboratory experimentation.

Product Overview

Retatrutide 20mg is a synthetic peptide belonging to the class of triple-receptor agonists. It is specifically designed for research environments to explore the interactions between GLP-1, GIP, and Glucagon signaling. Due to its potent activity at these three distinct sites, it is primarily used in studies focused on metabolic regulation and the biochemical foundations of cellular energy balance.

Specifications

Form: Lyophilised Powder Quantity: 20mg Purity: ≥99% (HPLC) Molecular Formula: C221H342N46O68 Storage: Store in a cool, dry place, away from direct light. For long-term stability, ensure the vial remains sealed until required for research.

Research Applications

In vitro and in vivo research involving Retatrutide focuses on its capacity to modulate insulin secretion, impact lipid metabolism, and influence satiety signaling through the glucagon receptor. Researchers utilise this compound to compare the efficacy of triple-agonism against dual-agonists (like Tirzepatide) or mono-agonists (like Semaglutide) to better understand the hierarchy of metabolic control. It is a critical subject in studies regarding thermogenesis and hepatic glucose production.

Research Use Notice

For laboratory research use only. Not for human or veterinary use.